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Introduction: Little is known about the responses of natriuretic peptides to developing congestive heart failure in
‘anephric’ end-stage kidney disease.
Case presentation: We present three consecutive cases of surgically-induced anephric patients in a critical care
environment: a 28-year-old Caucasian woman (with congestive heart failure), a 42-year-old Caucasian woman
(without congestive heart failure), and a 23-year-old Caucasian woman (without congestive heart failure). Our
limited study data indicate that cut-off values advocated for B-type natriuretic peptide and its N-terminal fragment
to ‘rule out’ congestive heart failure in two of our end-stage kidney disease patients (without congestive heart
failure) are largely appropriate for anephric patients. However, our index (first) patient developed congestive heart
failure accompanied by the phenomenon of massive and persistent elevation of these natriuretic levels.
Conclusion: Our findings suggest that patients from the anephric subclass suffering from congestive heart failure
will develop supramaximal elevation of B-type natriuretic peptide and its N-terminal fragment, implying the need
for dramatically higher cut-off values with respective magnitudes of the order of 50-fold (B-type natriuretic peptide
~5780pmol/L; 20,000ng/L) to 100-fold (N-terminal fragment ~11,800pmol/L; 100,000ng/L) higher than current
values used to ‘rule in’ congestive heart failure. Further research will be required to delineate those cut-off values.
The role of our devised ‘Blood Volume – B-type natriuretic peptide feedback control system’ on ‘anatomical’ and
‘functional’ anephric patients led to significant mathematically-enriched arguments supporting our proposal that
this model provides plausible explanations for the study findings, and the model lends support to the important
hypothesis that these two groups of anephric patients inflicted with congestive heart failure should effectively have
similar natriuretic response behavior.Introduction
Congestive heart failure (CHF) and renal failure (RF) act
synergistically to increase the levels of B-type natriuretic
peptide (BNP) and its co-secreted biologically inactive
N-terminal fragment (NT-proBNP). These two cardiac
neurohormones are mainly secreted from the ventricles
and, to a lesser extent, the atria. They have an established
role as useful diagnostic tests for CHF in both the pe-
diatric and adult population, including RF patients [1-3].* Correspondence: jycting@hotmail.com
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distribution, and reproduction in any mediumRF and CHF represent two merging pathologies with a
varying spectrum for speed of onset and severity. The
intersection of cardiac and renal insufficiency is referred
to as cardiorenal syndrome (Type 1 to 5) [4], which is
CHF as a result of RF or vice versa. Cardiac dysfunction
in end-stage kidney disease (ESKD) patients, whether
acute or chronic, is often due to disorders of perfusion
(ischemic heart disease) or to disorders of structure and
function. The disorders of structure and function and
CHF are often collectively termed ‘uremic cardiomyo-
pathy’ which is commonly associated with left ventricle
(LV) hypertrophy secondary to volume overload and hy-
pertension (HT). Cardiac disease accounts for >50% of
deaths in patients with ESKD [5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Available echocardiogram results in
chronological order
Patient CHF LVEF% (Timing in relation to Day 0 presentation)
1 Yes (i) 15–20% (Event X / 0 day), (ii) 45–50% (+23 days),
(iii) 30% (+6 months), (iv) 37% (+4.2 years), (v) 40%
(+4.3 years), and (vi) 30% with a large mitral valve
vegetation causing moderate to severe mitral
regurgitation (Event Y / +5 years)
2 No (i) 62% (+3 months)
3 No (i) 60% (−3.4 years), (ii) 68% (−2.5 months), and
(iii) 58% (+9 months)
CHF; Congestive heart failure, LVEF; Left ventricular ejection fraction.
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rity. Despite this, health care providers such as general
practitioners, emergency physicians, intensive care physi-
cians and anesthetists will probably come across these
anephric patients at some point in their working career.
Little is known about the magnitude of natriuretic rise in
response to developing CHF in this unique ‘anephric’
ESKD scenario.
We describe three consecutive SIA patients <60 years
of age requiring high acute care in an Intensive Care
Unit (ICU) or High Dependency Unit (HDU) at some
point in their life between May 2004 and December
2009. The patients were all Caucasian adult women fromTable 2 Available B-type natriuretic peptide, N-terminal fragm
Patient 1 SIA stage Creatinine, μmol/L BNP, pmo
Blood samples (Status)
1 (Pre; +5 months) 630 N/A
2 (Pre; +5.5 months) 600 N/A
3 (Pre; +8.75 months) 580 9410 [32,56
4 (Post; +8.75 months) 330 5478 [18,95
5 (Pre; +10.75 months) 600 N/A
6 (Post; +10.75 months) 210 N/A
7 (Pre; +5 years)β 518 N/A
βBlood sample obtained during terminal Event Y. Anti-hypertension methyld
Patient 2 SIA stage Creatinine, μmol/L BNP, pmol/
Blood samples (Status)
1 (Inter; +1 day) 763 79.2 [274; <
Patient 2 Post-SIA stage Creatinine, μmol/L BNP, pmol/
Blood samples (Status)
1 (Post-Tx; +19 months) 136 52 [180; <2
Patient 3 SIA stage Creatinine, μmol/L BNP, pmol/
Blood samples (Status)
1 (Inter; -7 days) 588 14.8 [51.4;
(Status): (Pre = ‘zenith’ pre-dialysis, Inter = ‘average’ inter-dialysis, Post = ‘nadir’ pos
0 presentation). N/A = nil available data.
For BNP and NT-proBNP, the two numerical values in parentheses refer to BNP or N
unit ng/L as outlined in Table 4 in Discussion section of this article. The different re
values to ‘rule out’ CHF being stratified for GFR. For prolactin, the numerical values
<500 mIU/L.
SIA; Surgically-induced anephric, BNP; B-type natriuretic peptide, NT-proBNP; N-terma regional catchment population of 200,000 people in
New South Wales, Australia. Using all information per-
taining to their presentation obtained over varying pe-
riods of time (before and during their SIA states, and after
having renal transplant in two of the three patients), in-
cluding hospital records, results of diagnostic imaging and
laboratory testing, we carefully studied each patient in
both a prospective and retrospective manner specifically
to determine the presence or absence of CHF.
The three subject patients were all on established
hemodialysis (HD) thrice weekly (Monday-Wednesday-
Friday schedule) for at least 30 days: the first session
(Monday) was the dialysis session after a 72-hour inter-
dialytic period whereas the second and third sessions were
after a 48-hour period. All three patients were under the
care of multidisciplinary teams; in particular under renal
physicians to comprehensively manage their HD or post-
renal transplant status.
The ‘zenith’ pre-dialysis, ‘nadir’ post-dialysis and ‘ave-
rage’ inter-dialysis body fluid levels meant that their reflec-
tive blood samples were to be collected at (respectively)
the start of a HD session, the end of a HD session
and on a HD-free day. Whenever possible, hematological
tests, biochemical tests, and specific hormone analysis for
prolactin (ARCHITECT Prolactin assay; Abbott), BNPent, and prolactin results in chronological order
l/L NT-proBNP, pmol/L Prolactin, pmol/L
N/A 27,561 [13,438]
N/A 41,682 [20,323]
3; >400] N/A 37,398 [18,234]
8; >400] N/A 37,923 [18,490]
25,060 [212,370; >1200] 26,868 [13,100]
14,814 [125,540; >1200] 18,254 [8,900]
16,846 [142,765; >1200] 8087 [3,943]
opa was ceased for one year prior to this.
L NT-proBNP, pmol/L Prolactin, pmol/L
225] N/A N/A
L NT-proBNP, pmol/L Prolactin, pmol/L
01] 32.45 [275; <300] 1103 [538]
L NT-proBNP, pmol/L Prolactin, pmol/L
<225] 118.47 [1004; <300] 1389 [677]
t-dialysis, Post-Tx = (successful) post-renal transplant; Timing in relation to Day
T-proBNP values with unit ng/L; reference range to ‘rule in’ or ‘rule out’ CHF in
ference range value (<201) quoted in Patient 2 Post-Tx is due to BNP cut-off

















































Figure 1 a. B-type natriuretic peptide (BNP) data on Patient 1
(surgically-induced anephric [SIA], congestive heart failure [CHF]). b.
N-terminal fragment (NT-proBNP) data on Patient 1 (surgically-
induced anephric [SIA], congestive heart failure [CHF]).
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nostics), and NT-proBNP (Elecsys® proBNP; Roche Diag-
nostics) were performed simultaneously on the same
blood sample. Relevant data such as pre-dialysis ‘wet’
weight (kg) and post-dialysis ‘dry’ weight (kg) are used to
estimate the net ultrafiltration volume removed as repre-
sented by a change in weight. Respectively, heart rate and
respiratory rate are given in beats/minute and breaths/mi-
nute. Blood pressure (BP) in mmHg is recorded as systolic
BP (SBP)/diastolic BP (DBP) with mean arterial pressure
(MAP) computed from invasive arterial pressure wave-
form. Those same BP parameters were computed via the
MAP = DBP + ⅓ (SBP – DBP) formula during electronic
non-invasive BP measurements. ‘Severe HT’ is defined
as SBP ≥180mmHg or DBP ≥120mmHg. ‘Resistant HT’
is defined as BP that remains above goal in spite of con-
current use of three anti-HT agents of different classes.
The goal BP is less than 140/90mmHg in average risk HT
patients.
Body mass index (BMI) is defined as (weight) ÷ (height)2
= kg/m2: normal (<25), overweight (25.0–29.9), and obese
(≥30). Chronic kidney disease (CKD) is based on the abbre-
viated Modification of Diet in Renal Disease equation [6]
to yield an estimated glomerular filtration rate (eGFR). We
utilize the 2002 Kidney Disease Outcomes Quality Initia-
tive of the National Kidney Foundation classification of the
stages of chronic RF or CKD with increasing severity as
CKD Stage 1 to 5. CHF can be LV systolic heart failure, LV
diastolic heart failure, or both. In this paper, the term CHF
is taken to be synonymous with ‘LV systolic heart failure’
with severity objectively classified by LV ejection fraction
(LVEF) into normal, >50%; moderate, 35%–50%; and se-
vere, <35%. LVEF values were obtained from all available
echocardiograms performed on the patients.
Case presentation
Patient 1
A 28-year-old Caucasian woman (BMI 22, normal) with
von Hippel–Lindau (VHL) syndrome had normal renal
function before she abruptly became a permanent SIA pa-
tient (an ESKD state, CKD Stage 5) resulting in severe HT
causing acute CHF (Event X) necessitating ICU admission
(Day 0). Thus, her renal function just prior to the SIA
state was normal. Her CHF became permanent and irre-
versible with the associated development of ‘intolerance
to ESKD’ persisting for 5 years until her death (Event Y).
Patient 2
A 42-year-old Caucasian woman (BMI 31, obese) with
polycystic kidney disease (PKD) was admitted to HDU
(Day 0) for post-operative care following subtotal pa-
rathyroidectomy for secondary hyperparathyroidism.
She was already in ESKD state before she transitioned
smoothly onto being a temporary SIA patient (also anESKD state) 1.5 years earlier. Thus, her renal function just
prior to the SIA state was ESKD. The ESKD component
from her SIA state was temporary for a period of just over
2 years before her subsequent successful renal transplant
(with resulting CKD Stage 3).
Patient 3
A 23-year-old Caucasian woman (BMI 24, normal), the
younger biological sister of Patient 1 and also inflicted
with VHL syndrome, was admitted to HDU (Day 0) for
post-operative care following a renal transplant. She
abruptly went into ESKD after becoming a SIA patient.
Thus, her renal function just prior to the SIA state was
normal. She was in this temporary SIA state for 4.5
months until this successful renal transplant (with resul-
ting CKD Stage 2).
For the interested reader, the clinical records on demo-
graphic and clinical characteristics of our subject patients
Figure 2 Blood Volume – B-type natriuretic peptide feedback control system. BV; Blood volume, CVP; Central venous pressure, BNP; B-type
natriuretic peptide.
Table 3 Quantity and quality of available B-type
natriuretic peptide (BNP) and N-terminal fragment (NT-
proBNP) results using arbitrary scales
Pre-SIA stage SIA stage Post-SIA stage
Quant. Qual. Quant. Qual. Quant. Qual.
- NA ++ √√ NA NA
- NA + √ + √√√
- NA + √√√ – NA
Quant. = Quantity of available results: – = Nil amount, + = Small amount, ++ =
Moderate amount, +++ = Large amount
Qual. = Quality of available results (based on number of tests able to be done
simultaneously on the same blood sample): √ = Fair, √√ = Good, √√√ =
Excellent
SIA; Surgically-induced anephric, NA; Not applicable.
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(portrayed in Additional file 1: Appendix 1). The complete
set of data collected in our study on echocardiograms and
blood test results is depicted in Tables 1 and 2 respec-
tively. In addition, BNP and NT-proBNP data from Pa-
tient 1 are depicted in Figure 1a and 1b respectively. All
patients fulfilled the criteria for being in SIA state at some
stage in their life. Our index (first) patient developed CHF.
The remaining two patients did not develop CHF and they
also had eventual renal transplants. This case mix of
patients with and without CHF (on clinical grounds and
objectively confirmed by echocardiograms) was necessary
for analyzing cut-off values for natriuretic peptides to ‘rule
in’ and ‘rule out’ CHF in anephric patients (respectively).
Discussion
Predominantly based on concepts behind the feedback
control systems, we devise the ‘Blood Volume (BV) –
BNP feedback control system’ (Figure 2) with further
discourse in Additional file 2: Appendix 2 to help pro-
vide plausible explanations for our findings.
For the interested reader, our intentional in-depth dis-
section on the study strengths, limitations and main fin-
dings (Additional file 3: Appendix 3) were tailored to
provide some grounding for our recommended recruit-
ment of minimum subject numbers for, and some aid todesign, future study on a similar research topic. We also
included an arbitrary evaluation on quantity and quality
of the complete set of data collected in our study
(Table 3) in Additional file 3: Appendix 3. Table 4 de-
picts currently available diagnostic cut-off values for
BNP and NT-proBNP [2,7,8] to ‘rule in’ or ‘rule out’
CHF (stratified for age and GFR with data from patients
with eGFR <15 mL/minute/1·73 m2 or those on renal
dialysis therapy excluded).
From the study strengths, limitations and main findings
expounded in Additional file 3: Appendix 3, the main
Table 4 Cut-off values of B-type natriuretic peptide (BNP) and N-terminal fragment (NT-proBNP) as diagnostic tests to
‘rule out’ and ‘rule-in’ congestive heart failure (CHF)§
‘Rule out’ CHF ‘Rule in’ CHF
BNP cut-off values to ‘rule out’ CHF: <100ng/L. BNP cut-off values to ‘rule in’ CHF: >400ng/L.





NT-proBNP cut-off value to ‘rule out’ CHF: <300ng/L. NT-proBNP cut-off value to ‘rule in’ CHF.
When stratified for age, When stratified for GFR,
Age <50 year: >450ng/L. GFR >60mL/minute: >900ng/L.
Age 50–75 year: >900ng/L. GFR <60mL/minute: >1200ng/L.
Age >75 year: >1800ng/L.
§Reflects a nomogram version of Bayes’ Theorem, in diagnosis-uncertain patients (pre-test probabilities of ~50%), a likelihood ratio for a positive test result ≥10 is
required to ‘rule in’ disease with reasonable certainty (post-test probability ≥90%) where a positive test result = (sensitivity) / (1 – specificity) = true positives /
false positives ratio; whereas likelihood ratio for a negative test result ≤0·10 is required to ‘rule out’ disease with reasonable certainty (post-test probability ≤10%)
where a negative test result = (1 – sensitivity) / (specificity) = false negatives / true negatives ratio).
CHF; Congestive heart failure, BNP; B-type natriuretic peptide, GFR; Glomerular filtration rate, NT-proBNP; N-terminal fragment.
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our results largely supported the quoted cut-off values
advocated for BNP and NT-proBNP to ‘rule out’ CHF but
not to ‘rule in’ CHF whereby dramatically higher cut-
off values for BNP ~5780pmol/L (20,000ng/L) and NT-
proBNP ~11,800pmol/L (100,000ng/L) will apparently be
required. However, in contrast to our interpretation, using
the recommended cut-off values of BNP <100ng/L and
NT-proBNP <125ng/L for exclusion of CHF, Zuber et al.
[9] have previously shown in 2009 that those chosen cut-
off values fail to adequately ‘rule-out’ CHF in their 384
subject patients from a population with a high prevalence
of CHF (50% with systolic heart failure and 8% with iso-
lated diastolic heart failure). The BNP was a false negative
in 25% of their patients and NT-proBNP was a false nega-
tive in 10% of their patients.
From Additional file 2: Appendix 2, we cater for better
overall comprehension for general readers by alerting
them to the following simplified explanatory remarks on
the secondary endpoint of our study, which was to de-
monstrate supramaximal elevation of prolactin in Patient
1. This is based on analogous physiologic mechanisms
that resulted in the demonstrated supramaximal natri-
uretic peptides levels (primary endpoint of our study) in
the same patient. The supramaximal prolactin levels in
this patient were due to the overall magnitude of rises in
prolactin (arising from the effects of individual factors
and/or causes of prolactin endocrine disorder that tend
to increase prolactin production and/or decrease prolactin
clearance) ‘far outstripping’ the overall magnitude of falls
in prolactin (arising from the effects of individual factors
and/or causes of prolactin endocrine disorder that tend
to decrease prolactin production and/or increase prolactinclearance). To put our research in perspective, a crucial
comment to make is that except to greatly aid in explai-
ning the occurrence of supramaximal elevation pheno-
mena for hormones in general, we acknowledge that the
prolactin data per se in our manuscript do not help in per-
taining to ‘rule in’ or ‘rule out’ CHF using biomarkers in
any patients, not even in anephric patients.
In theory, the truly anephric state represents a unique
position for research purposes because any ‘distorting
interferences’ from a failing kidney are eliminated from
consideration. These interferences refer mainly to the
kidney (an integral component of the feedback control
system) acting as: (1) an and/or the end target-organ for
the relevant hormones; and/or (2) an and/or the organ
contributing to metabolic clearance rate (MCR) for the
relevant hormones. This ‘significant elimination’ holds
true for the first interference (with the associated loss of
the kidney compensatory pathway) but less so for the
second interference because: (i) anephric patients are
dependent on, usually, intermittent HD to keep them
alive and thus providing them with an artificial means to
intermittently and variably clear relevant hormones
(namely, BNP and NT-proBNP); and (ii) there may be
non-renal pathways (via other organs or tissues) variably
contributing to MCR for these relevant hormones as
well. This study should offer further research insights
into the biological organization of the human body at
the system level emphasizing adaptive and integrative
mechanisms. This will advance our knowledge of phy-
siology thus increasing our understanding of how our
bodies function in health and disease.
For the interested reader, elucidation of utilizing a
branch of mathematics known as combinatorics and step-
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feedback control system (as demonstrated in Additional
file 2: Appendix 2) has led to plausible explanations for
our study findings, and lent support to the important hy-
pothesis that ‘anatomical’ and ‘functional’ anephric pa-
tients inflicted with CHF should effectively have similar
natriuretic response behavior.Conclusion
Despite this study achieving the primary endpoint of
demonstrating (sustained) supramaximal elevations of
BNP and NT-proBNP in only one (obtainable) anephric
patient inflicted with CHF (which suggested the need for
dramatically higher BNP and NT-proBNP cut-off values
for anephric patients in CHF with respective magnitudes
of the order of 50-fold to 100-fold higher than the usual
figures quoted to ‘rule in’ CHF), we were of the opinion
that this should serve as a basis for future research
aimed at further delineating the cut-off values for those
hormones to diagnose CHF in anephric patients utilizing
chemical biomarkers, thus enhancing the management
of their cardiac disease. All these should broaden the
knowledge of clinicians treating these patients and publi-
cize the potential deleterious effect of not interpreting
BNP and NT-proBNP tests appropriately in this setting.
Based on elegant mathematical deductions, the BV –
BNP feedback control system provides plausible explana-
tions for our study findings, and lends support to the
important hypothesis that ‘anatomical’ and ‘functional’
anephric patients inflicted with CHF should effectively
have similar natriuretic response behavior.Consent
Written informed consents were obtained from the
patients for publication of this case report. Copies of the
written consents are available for review by the Editor-
in-Chief of this journal.Additional files
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